September 2023
A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
Richert et Al.
May 2023
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
Chettab et al.
February 2020
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8‑positive cytotoxic lymphocytes
Yahiro et al.
October 2018
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Grassely et al.
January 2017
Structural and biological characteristics of different forms of V. filiformis lipid A: use of MS to highlight structural discrepancies
Breton et al.
November 1986
Inability of pyrogenic, purified Bordetella pertussis lipid A to induce interleukin-1 release by human monocytes
Caroff et al.
